<html><head></head><body><h1>Altafluor</h1><p class="drug-subtitle"><b>Generic Name:</b> fluorescein sodium and benoxinate hydrochloride<br/>
<b>Dosage Form:</b> ophthalmic solution<br/></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Dosage</li>
<li><b class="nav-item here">Professional</b></li>
<li>Interactions</li>
<li class="nav-more">
More&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewBox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/body&gt;&lt;/html&gt;
</li>
</ul><ul>
<li>Indications and Usage</li>
<li>Dosage and Administration</li>
<li>Dosage Forms and Strengths</li>
<li>Contraindications</li>
<li>Warnings and Precautions</li>
<li>Adverse Reactions/Side Effects</li>
<li>Use In Specific Populations</li>
<li class="ddc-toggle-hidden">Description</li>
<li class="ddc-toggle-hidden">Clinical Pharmacology</li>
<li class="ddc-toggle-hidden">Nonclinical Toxicology</li>
<li class="ddc-toggle-hidden">Clinical Studies</li>
<li class="ddc-toggle-hidden">How Supplied/Storage and Handling</li>
<li class="ddc-toggle-hidden">Patient Counseling Information</li>
</ul><h2>1 INDICATIONS AND USAGE</h2><p class="First"><span class="Bold">Altafluor Benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution) 0.25%/0.4% is indicated for ophthalmic procedures requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent.</span></p><h2>2 DOSAGE AND ADMINISTRATION</h2><p class="First"><span class="Bold">Instill 1 to 2 drops of Altafluor Benox in the eye as needed.</span></p><h2>3 DOSAGE FORMS AND STRENGTHS:</h2><p class="First"><span class="Bold">Altafluor Benox is a yellow to orange-red ophthalmic solution containing fluorescein sodium 2.5 mg/mL (0.25%) and benoxinate hydrochloride 4 mg/mL (0.4%).</span></p><h2>4 CONTRAINDICATIONS:</h2><p class="First"><span class="Bold">Altafluor Benox is contraindicated in patients with known hypersensitivity to any component of this product.</span></p><h2>5 WARNINGS AND PRECAUTIONS</h2><h3>5.1 Corneal Toxicity</h3><p class="First">Prolonged use or abuse may lead to corneal epithelial toxicity which may manifest as epithelial defects and progress to permanent corneal opacification with accompanying visual loss.</p><h3>5.2 Corneal Injury Due to Insensitivity</h3><p class="First">Patient should not touch the eye for approximately 20 minutes after using this anesthetic as accidental injuries can occur due to insensitivity of the eye.</p><h2>6 ADVERSE REACTIONS</h2><p class="First"><span class="Bold">The following ocular adverse reactions are described elsewhere in the labeling:</span></p><ul class="Disc">
<li><span class="Bold">Corneal Toxicity <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"> </span><span class="Italics">Warnings and Precautions (5.1)</span><span class="Italics">]</span><br/></span></li>
<li>Corneal Injury due to Insensitivity <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"> </span><span class="Italics">Warnings and Precautions (5.2)</span><span class="Italics">]</span></li>
</ul><p>The following adverse reactions have been identified following use of fluorescein sodium and benoxinate hydrochloride ophthalmic solution 0.25% / 0.4%: ocular hyperemia, burning, stinging, eye irritation, blurred vision and punctate keratitis. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><h2>8 USE IN SPECIFIC POPULATIONS</h2><h3>8.1 Pregnancy</h3><p class="First"><span class="Bold">Risk Summary</span> </p><p>There are no available data on the use of Altafluor Benox in pregnant women to inform any drug associated risk. Adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. Altafluor Benox should be given to a pregnant woman only if clearly needed.</p><h3>8.2 Lactation</h3><p class="First"><span class="Bold">Risk Summary</span> </p><p>There are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of Altafluor Benox, the effects on the breastfed infant, or the effects on milk production.</p><p>The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for Altafluor Benox and any potential adverse effects on the breastfed infant from Altafluor Benox.</p><h3>8.4 Pediatric Use</h3><p class="First">The safety and effectiveness of Altafluor Benox have been established for pediatric patients. Use of Altafluor Benox is supported in pediatric patients by evidence from adequate and well controlled studies.</p><h3>8.5 Geriatric Use</h3><p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p><h2>11 DESCRIPTION</h2><p class="First"><span class="Bold">Altafluor Benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution) 0.25%/0.4% is a sterile disclosing agent in combination with a short-acting ester anesthetic for topical ophthalmic use.</span></p><p><span class="Bold">Fluorescein sodium is represented by the following structural formula:  </span></p><p><span class="Bold"> </span></p><p><span class="Bold">C<span class="Sub">20</span>H<span class="Sub">10</span>Na<span class="Sub">2</span>O<span class="Sub">5</span>                                                   Mol. Wt. 376.27</span></p><p>Chemical Name: Spiro [isobenzofuran-1 (3<span class="Italics">H</span>),9’-9[9<span class="Italics">H</span>] xanthene]-3-one, 3’,6’ dihydroxy, disodium salt.</p><p>Benoxinate hydrochloride is represented by the following structural formula:</p><p> </p><p>C<span class="Sub">17</span>H<span class="Sub">28</span>N<span class="Sub">2</span>O<span class="Sub">3</span> • HCl                                                 Mol. Wt. 344.88</p><p>Chemical Name: 2-(Diethylamino) etyl 4-amino-3-butoxybenzoate monohydrochloride.</p><p>Each mL contains: Actives: fluorescein sodium 2.5 mg (0.25%) equivalent to fluorescein 2.2 mg (0.22%), benoxinate hydrochloride 4 mg (0.4%) equivalent to benoxinate 3.6 mg (0.36%); Inactives: povidone, hydrochloric acid, boric acid, sodium hydroxide, water for injection. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH (4.3 – 5.3). Preservative: chlorobutanol 11mg (1.1%).</p><h2>12. CLINICAL PHARMACOLOGY</h2><p class="First"><span class="Bold">This product is the combination of a disclosing agent with a rapidly acting ester anesthetic of short duration.</span></p><h3>12.2 Pharmacodynamics</h3><p class="First">Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration. The anesthetic effect may be extended by subsequent administration 10-20 minutes after the last administration.</p><h2>13 NONCLINICAL TOXICOLOGY</h2><h3>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h3><p class="First">Long-term studies to evaluate the carcinogenic potential of Altafluor Benox have not been conducted.</p><h2>14 CLINICAL STUDIES</h2><p class="First"><span class="Bold">Controlled clinical studies in adults and pediatric patients have demonstrated that topical administration of fluorescein sodium and benoxinate hydrochloride ophthalmic solution 0.25%/0.4% enables visualization and corneal anesthesia sufficient to enable applanation tonometry, tear fluid dynamics evaluation and short conjunctival and corneal procedures. Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration.</span></p><h2>16 HOW SUPPLIED/STORAGE AND HANDLING</h2><p class="First"><span class="Bold">Altafluor Benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution) 0.25%/0.4% is a sterile, yellow to orange-red solution supplied in a 5 mL glass bottle with a sterilized dropper.</span></p><p><span class="Bold">NDC #59390-218-05</span></p><p><span class="Bold"><span class="Bold">Storage</span>: Store in refrigerator at 2° to 8°C (36° to 46°F).  After opening, Altafluor Benox can be stored up to one month if stored at room temperature or until the expiration date on the bottle if stored in refrigerated conditions. Keep tightly closed.</span></p><h2>17 PATIENT COUNSELING INFORMATION</h2><p class="First"><span class="Bold"><span class="Bold">Accidental Injury</span> <span class="Bold">Precaution</span></span></p><p>Advise patients not to touch their eyes for approximately 20 minutes after application. Their eyes will be insensitive due to the effect of the anesthetic, and care should be taken to avoid accidental injuries.</p><p>Rev. 12/2017                                   </p><p>Manufactured by:<br/>
ALTAIRE Pharmaceuticals, Inc.                                          <br/>
Aquebogue, NY 11931</p><h2>PRINCIPAL DISPLAY PANEL</h2><p class="First">NDC 59390-218-05<br/>
Altafluor<br/>
BENOX<br/>
Fluorescein Sodium and<br/>
Benoxinate Hydrochloride<br/>
Ophthalmic Solution, USP <br/>
0.25%/0.4%<br/>
(Sterile)<br/>
5 mL<br/>
Rx Only</p><p></p><h2>More about Altafluor (benoxinate / fluorescein ophthalmic)</h2><ul class="more-resources-list more-resources-list-general">
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: ophthalmic diagnostic agents</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>